{"id":{"repo_id":"qu-belfast","oai_identifier":"oai:pure.qub.ac.uk/portal:studenttheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e"},"canonical_url":"https://search.dev.ndltd.org/etd/qu-belfast/oai:pure.qub.ac.uk/portal:studenttheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e","repository":{"repo_id":"qu-belfast","name":"Queen's University Belfast","base_url":"https://pureadmin.qub.ac.uk/ws/oai"},"display":{"title":"Exacerbation and glucocorticoid toxicity profile in patients receiving mepolizumab for severe eosinophilic asthma","abstract":"The treatment of patients with severe eosinophilic asthma has been transformed with the arrival of biological drugs targeting the type 2 cytokine pathway. One of these drugs is mepolizumab, a humanised monoclonal antibody against the eosinophil activating cytokine, interleukin (IL)-5, has consistently been shown to lead to a 50% reduction in exacerbation rate, when compared with placebo, and facilitates the weaning of maintenance oral corticosteroids (OCS) in patients with severe eosinophilic asthma. <br/><br/>This works seeks to address two questions that arise from treatment with this novel monoclonal antibody:<br/><br/>1. What is the inflammatory phenotype and the physiological characteristics of the residual asthma exacerbations that occur in patients with severe eosinophilic asthma treated with anti-IL5 monoclonal antibodies?<br/><br/>2. To quantify toxicity associated with OCS treatment in severe eosinophilic asthmatics, and assess change in OCS-related toxicity after 1 year's treatment with mepolizumab and subsequent reduction in OCS, both through weaning of maintenance OCS and reduction in OCS for asthma exacerbations.","abstract_html":"The treatment of patients with severe eosinophilic asthma has been transformed with the arrival of biological drugs targeting the type 2 cytokine pathway. One of these drugs is mepolizumab, a humanised monoclonal antibody against the eosinophil activating cytokine, interleukin (IL)-5, has consistently been shown to lead to a 50% reduction in exacerbation rate, when compared with placebo, and facilitates the weaning of maintenance oral corticosteroids (OCS) in patients with severe eosinophilic asthma. &lt;br/&gt;&lt;br/&gt;This works seeks to address two questions that arise from treatment with this novel monoclonal antibody:&lt;br/&gt;&lt;br/&gt;1. What is the inflammatory phenotype and the physiological characteristics of the residual asthma exacerbations that occur in patients with severe eosinophilic asthma treated with anti-IL5 monoclonal antibodies?&lt;br/&gt;&lt;br/&gt;2. To quantify toxicity associated with OCS treatment in severe eosinophilic asthmatics, and assess change in OCS-related toxicity after 1 year&#x27;s treatment with mepolizumab and subsequent reduction in OCS, both through weaning of maintenance OCS and reduction in OCS for asthma exacerbations.","abstract_has_math":false,"creators":["McDowell, Pamela Jane"],"institution":"Queen's University Belfast","degree_name":"Doctor of Philosophy","degree_level":"Doctoral Thesis","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Heaney, Liam","McGarvey, Lorcan"],"committee_chairs":[],"committee_members":[],"year":2022,"date_issued":"2022-12","date_published":"2022-12","updated_at":"2026-07-24T03:56:18Z","subjects":["Asthma","eosinophilic","T2 high","monoclonal antibodies"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["oai:pure.qub.ac.uk/portal:studenttheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e"],"render_values":[{"text":"oai:pure.qub.ac.uk/portal:studenttheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e","href":null,"code":true}]}]},"links":{"outbound_url":"https://pure.qub.ac.uk/en/studentTheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Heaney, Liam","McGarvey, Lorcan"]},{"key":"dc:contributor.sponsor","label":"Sponsor","values":["United Kingdom Medical Research Council Refractory Asthma Stratification Programme"]},{"key":"dc:creator","label":"Author","values":["McDowell, Pamela Jane"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2022-12"]},{"key":"dc:date.issued","label":"Date","values":["2022-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["School of Medicine, Dentistry and Biomedical Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["Queen's University Belfast"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://pure.qub.ac.uk/en/studentTheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Doctoral Thesis"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["Doctor of Philosophy"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Asthma","eosinophilic","T2 high","monoclonal antibodies"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["oai:pure.qub.ac.uk/portal:studenttheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e","https://pure.qub.ac.uk/en/studentTheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://pure.qub.ac.uk/files/297759534/Thesis_McDowell_pdf.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The treatment of patients with severe eosinophilic asthma has been transformed with the arrival of biological drugs targeting the type 2 cytokine pathway. One of these drugs is mepolizumab, a humanised monoclonal antibody against the eosinophil activating cytokine, interleukin (IL)-5, has consistently been shown to lead to a 50% reduction in exacerbation rate, when compared with placebo, and facilitates the weaning of maintenance oral corticosteroids (OCS) in patients with severe eosinophilic asthma. <br/><br/>This works seeks to address two questions that arise from treatment with this novel monoclonal antibody:<br/><br/>1. What is the inflammatory phenotype and the physiological characteristics of the residual asthma exacerbations that occur in patients with severe eosinophilic asthma treated with anti-IL5 monoclonal antibodies?<br/><br/>2. To quantify toxicity associated with OCS treatment in severe eosinophilic asthmatics, and assess change in OCS-related toxicity after 1 year's treatment with mepolizumab and subsequent reduction in OCS, both through weaning of maintenance OCS and reduction in OCS for asthma exacerbations."]},{"key":"dc:title","label":"Title","values":["Exacerbation and glucocorticoid toxicity profile in patients receiving mepolizumab for severe eosinophilic asthma"]}]}],"canonical_facts":{"dc:contributor.advisor":["Heaney, Liam","McGarvey, Lorcan"],"dc:contributor.sponsor":["United Kingdom Medical Research Council Refractory Asthma Stratification Programme"],"dc:creator":["McDowell, Pamela Jane"],"dc:date":["2022-12"],"dc:date.issued":["2022-12"],"dc:description.abstract":["The treatment of patients with severe eosinophilic asthma has been transformed with the arrival of biological drugs targeting the type 2 cytokine pathway. One of these drugs is mepolizumab, a humanised monoclonal antibody against the eosinophil activating cytokine, interleukin (IL)-5, has consistently been shown to lead to a 50% reduction in exacerbation rate, when compared with placebo, and facilitates the weaning of maintenance oral corticosteroids (OCS) in patients with severe eosinophilic asthma. <br/><br/>This works seeks to address two questions that arise from treatment with this novel monoclonal antibody:<br/><br/>1. What is the inflammatory phenotype and the physiological characteristics of the residual asthma exacerbations that occur in patients with severe eosinophilic asthma treated with anti-IL5 monoclonal antibodies?<br/><br/>2. To quantify toxicity associated with OCS treatment in severe eosinophilic asthmatics, and assess change in OCS-related toxicity after 1 year's treatment with mepolizumab and subsequent reduction in OCS, both through weaning of maintenance OCS and reduction in OCS for asthma exacerbations."],"dc:identifier":["oai:pure.qub.ac.uk/portal:studenttheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e","https://pure.qub.ac.uk/en/studentTheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e"],"dc:identifier.uri":["https://pure.qub.ac.uk/files/297759534/Thesis_McDowell_pdf.pdf"],"dc:language":["eng"],"dc:publisher.department":["School of Medicine, Dentistry and Biomedical Sciences"],"dc:publisher.institution":["Queen's University Belfast"],"dc:relation.isreferencedby":["https://pure.qub.ac.uk/en/studentTheses/3dd2c418-704c-4be0-9c52-6fa49ff8263e"],"dc:subject":["Asthma","eosinophilic","T2 high","monoclonal antibodies"],"dc:title":["Exacerbation and glucocorticoid toxicity profile in patients receiving mepolizumab for severe eosinophilic asthma"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["Doctoral Thesis"],"dc:type.qualificationname":["Doctor of Philosophy"]},"updated_at":"2026-07-24T03:56:18Z"}